Clinical trial · Observational
Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer
Study Of The Expression Of Circulating And Intra-Tumoral Chemokines In Patients With Prostate Cancer
NCT02869282CI-TRIAL-00095260CHEMOPROSTwithdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Principal investigator left the study center and nobody took over the study.
Summary
Brief summary (as posted)
Multicentric, observational, prospective, non-interventional study with occasional biological sample collection (serum bank, urine bank and tumor bank)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Other | — | UNRESOLVED |
| Urine samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Prospective cohort
- description
- Levels of CXCL1, CCL5, CXCL8 and CXCL12 chemokines and of IL-6 cytokine by ELISA or Luminex technology.
- interventionNames
- Other: Blood samples
- Other: Urine samples
Primary outcomes (2)
- measure
- Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical
- timeFrame
- At baseline
- measure
- Concentration of chemokines initially detectable in the blood or urine and evolution during follow-up: CXCL1, CXCL5, CXCL8, CXCL12, cytokine IL-6. Measurement was made by Luminex or elisa technical
- timeFrame
- At 6 months
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with a localized or metastatic prostate adenocarcinoma for which a new treatment will be implemented (hormone therapy for single biological relapse or relapses and metastatic hormone-sensitive) or chemotherapy (for biological relapses and / or metastatic hormone-resistant) * Patients with a detectable PSA (Prostate-Specific Antigen) * Patients who signed an informed consent * Patients over 18 years * Patients belonging to the social security scheme Exclusion Criteria: * Active Hepatitis B or C virus * HIV positive * Patients who have received prior chemotherapy * Patients with a second neoplasia treated in the last 5 years
References
Publications (0)
Data not yet available
No reference posted for this study.